These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19883402)

  • 21. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].
    Garrison LP; Pauly MV; Willke RJ; Neumann PJ
    Value Health; 2018 Feb; 21(2):124-130. PubMed ID: 29477389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
    Neumann PJ; Willke RJ; Garrison LP
    Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.
    Johnson ML; Crown W; Martin BC; Dormuth CR; Siebert U
    Value Health; 2009; 12(8):1062-73. PubMed ID: 19793071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report.
    Malone DC; Ramsey SD; Patrick DL; Johnson FR; Mullins CD; Roberts MS; Willke RJ; Marshall DA
    Value Health; 2020 Apr; 23(4):409-415. PubMed ID: 32327155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
    Jansen JP; Fleurence R; Devine B; Itzler R; Barrett A; Hawkins N; Lee K; Boersma C; Annemans L; Cappelleri JC
    Value Health; 2011 Jun; 14(4):417-28. PubMed ID: 21669366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the rise in American pharmaceutical prices.
    Marwaha A
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(2):11-5. PubMed ID: 12099112
    [No Abstract]   [Full Text] [Related]  

  • 30. American pharmaceutical prices.
    Alagona P
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58. PubMed ID: 12592980
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].
    Danzon PM; Drummond MF; Towse A; Pauly MV
    Value Health; 2018 Feb; 21(2):140-145. PubMed ID: 29477391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
    Lichtenberg FR
    Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Economical evaluation of drugs. A steering method for the pharmaceutical sector of the 1990's?].
    Grund J; Husbyn H
    Tidsskr Nor Laegeforen; 1994 Mar; 114(8):947-50. PubMed ID: 8191475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Will lower drug prices jeopardize drug research? A policy fact sheet.
    Light DW; Lexchin J
    Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
    [No Abstract]   [Full Text] [Related]  

  • 37. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.
    Detsky AS
    Pharmacoeconomics; 1993 May; 3(5):354-61. PubMed ID: 10146886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. When will the U.S. flinch at cancer drug prices?
    Vanchieri C
    J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
    [No Abstract]   [Full Text] [Related]  

  • 39. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
    Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
    Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report.
    Brazier J; Ara R; Azzabi I; Busschbach J; Chevrou-Séverac H; Crawford B; Cruz L; Karnon J; Lloyd A; Paisley S; Pickard AS
    Value Health; 2019 Mar; 22(3):267-275. PubMed ID: 30832964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.